
Devyser webinar
Devyser RHD*: High performance without complexity
Date and time: April 29, 2025 | 4pm CET | 10am ET
Get the complete picture of why Devyser RHD sets a new standard for fetal RHD screening.
- Simple by design
Discover how Devyser RHD’s unique single-exon assay simplifies analysis and reduces inconclusive results. With few steps and a streamlined workflow, it’s easier than ever to implement reliable fetal RHD genotyping into your lab routine.
- Performance in clinical use
Backed by large-scale validation studies, Devyser RHD delivers 99.9% sensitivity and 99.95% specificity, helping avoid unnecessary prophylaxis and ensure confident clinical decisions as early as week 10 of pregnancy.
- Trusted in practice
With over 100,000 pregnancies tested, 12 years of product expertise, and CE-IVDR, Risk Class D, certification, Devyser RHD is a proven, trusted solution in national screening programs and high-throughput settings.
Don't miss this opportunity to explore how Devyser RHD shapes non-invasive RHD genotyping.
Feel free to submit your questions beforehand if you want them addressed during the webinar.
*Disclaimer: Devyser products are distributed worldwide. Not all intended uses and applications mentioned here are available in every country. Please consult your local sales representative for details.
Latest from the Devyser blog
View all

Devyser launches a new updated NGS assay to simplify thalassemia testing
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed...
Read More

Devyser Thalassemia achieves 99.9% sensitivity: Insights from a recent study
Thalassemia and hemoglobinopathies are among the most common genetic disorders worldwide, affecting...
Read More